Alkaloid Skopje : marked 12% growth in consolidated export, 6% growth in consolidated net profit, investments of MKD 873.5 million and 144 new employments in the Republic of Macedonia in the period January - September 2018

31.10.2018

Alkaloid AD Skopje achieved positive financial results in the period January-September 2018 - shows the unaudited standalone and unaudited consolidated Income Statement.

According to the unaudited standalone Income Statement, in the period January- September the sales reached the amount of MKD 5,517,737,841 - 7% up on the same period last year. Earnings before interest, taxes, depreciation and amortization (EBITDA), which amount to MKD 1,070,876,587 marked an increase of roughly 9%, whereas the net profit amounting to MKD 611,467,420 rose by 8%.

In the period January - September the total consolidated sales reached MKD 7,216,850,652 - an increase of 9% compared to the same period last year. Consolidated sales in the domestic market increased 4%, while the total consolidated export of the company increased by 12%. Out of the total consolidated sales, 37% were realized in the domestic market, while the foreign markets account for 63%. The breakdown by region shows that the countries of South-East Europe account for 34% of the sales, Russia and CIS - 6%, 21% of the sales were realized in the countries from Western Europe (EU and EFTA), while the other markets account for 2% of the total consolidated sales. Noticeable rise was seen in Hungary reaching sales of MKD 103,199,347 - increased by 4.3 times, Poland reaching sales of MKD 37,782,977 - increased by 3.5 times and Ukraine with sales of MKD 125,214,639 - increased by 2.2 times compared to the same period last year. Growth in sales was also marked in the following export markets: Czech Republic - 149%, USA - 86%, Georgia - 27%, Serbia - 25%, Romania - 22%, Kosovo - 21%, etc.

The breakdown of total consolidated sales by group of products shows that the best sellers are the products from the segment Pharmaceuticals - 84%, with OTC products accounting for 21%, cardiovascular products - 17%, antibiotics - 14%, neurological products - 13% etc. The Chemistry Cosmetics Botanicals segment accounts for 16% of the total consolidated sales, or more precisely Chemistry - 3%, Cosmetics - 10% and Botanicals - 3%.

Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), which reached MKD 1,094,886,703 saw an increase of 7%, whereas the net consolidated profit amounting to MKD 587,392,889 went up by 6%.

The total investments in non-current assets for the period January - September 2018 amounted to MKD 873,482,122 - an increase of 69% compared to 2017.

In the period January - September 2018 Alkaloid recruited 144 new employees in the Republic of Macedonia.